Amedisys Stock Total Debt

AMED Stock

USD 91.24 0.84 0.93%

Amedisys fundamentals help investors to digest information that contributes to Amedisys' financial success or failures. It also enables traders to predict the movement of Amedisys Stock. The fundamental analysis module provides a way to measure Amedisys' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amedisys stock.

Short Long Term Debt Total Total Assets

The current year's Total Debt To Capitalization is expected to grow to 0.45.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Amedisys Company Total Debt Analysis

Amedisys' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Total Debt

Bonds

+

Notes

More About Total Debt | All Equity Analysis

Current Amedisys Total Debt

487.21 M

Most of Amedisys' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amedisys is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Amedisys Total Debt Driver Correlations

Understanding the fundamental principles of building solid financial models for Amedisys is extremely important. It helps to project a fair market value of Amedisys Stock properly, considering its historical fundamentals such as Total Debt. Since Amedisys' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Amedisys' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Amedisys' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Current Deferred Revenue	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Good Will	Intangible Assets	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.99	0.9	0.95	0.6	0.95	0.99	0.95	0.9	0.76	0.53	0.94	-0.92	-0.24	0.98	0.89	-0.81	0.29	0.88	0.85	0.4	0.72	0.8	0.91	-0.64	0.81
Total Stockholder Equity	0.99		0.86	0.93	0.64	0.97	0.97	0.95	0.88	0.76	0.58	0.92	-0.9	-0.24	0.97	0.88	-0.75	0.27	0.84	0.85	0.35	0.71	0.79	0.88	-0.62	0.79
Net Debt	0.9	0.86		0.9	0.56	0.78	0.91	0.74	0.83	0.63	0.37	0.98	-0.88	-0.17	0.92	0.91	-0.87	0.34	0.9	0.76	0.5	0.76	0.62	0.94	-0.56	0.65
Retained Earnings	0.95	0.93	0.9		0.47	0.87	0.94	0.85	0.87	0.81	0.29	0.94	-0.95	-0.37	0.98	0.88	-0.92	0.49	0.94	0.81	0.63	0.78	0.81	0.95	-0.66	0.84
Accounts Payable	0.6	0.64	0.56	0.47		0.66	0.58	0.56	0.43	0.13	0.78	0.52	-0.59	-0.05	0.57	0.72	-0.33	0.07	0.26	0.69	0.06	0.31	0.08	0.51	-0.6	0.17
Net Receivables	0.95	0.97	0.78	0.87	0.66		0.93	0.98	0.84	0.7	0.61	0.84	-0.88	-0.3	0.92	0.84	-0.68	0.34	0.76	0.86	0.34	0.66	0.76	0.8	-0.64	0.76
Total Liab	0.99	0.97	0.91	0.94	0.58	0.93		0.93	0.9	0.73	0.49	0.95	-0.91	-0.23	0.98	0.89	-0.84	0.31	0.89	0.84	0.44	0.69	0.79	0.92	-0.67	0.81
Total Current Assets	0.95	0.95	0.74	0.85	0.56	0.98	0.93		0.85	0.73	0.57	0.82	-0.83	-0.3	0.9	0.78	-0.66	0.29	0.76	0.82	0.3	0.63	0.82	0.78	-0.58	0.81
Short Term Debt	0.9	0.88	0.83	0.87	0.43	0.84	0.9	0.85		0.74	0.33	0.85	-0.75	-0.06	0.87	0.77	-0.72	0.32	0.84	0.65	0.36	0.61	0.8	0.83	-0.49	0.81
Current Deferred Revenue	0.76	0.76	0.63	0.81	0.13	0.7	0.73	0.73	0.74		0.16	0.71	-0.68	-0.4	0.76	0.56	-0.66	0.27	0.81	0.59	0.37	0.75	0.9	0.74	-0.22	0.85
Common Stock	0.53	0.58	0.37	0.29	0.78	0.61	0.49	0.57	0.33	0.16		0.39	-0.42	0.12	0.42	0.57	-0.08	-0.25	0.14	0.67	-0.26	0.34	0.17	0.36	-0.36	0.28
Long Term Debt	0.94	0.92	0.98	0.94	0.52	0.84	0.95	0.82	0.85	0.71	0.39		-0.89	-0.23	0.96	0.91	-0.88	0.33	0.95	0.79	0.47	0.79	0.74	0.96	-0.54	0.74
Treasury Stock	-0.92	-0.9	-0.88	-0.95	-0.59	-0.88	-0.91	-0.83	-0.75	-0.68	-0.42	-0.89		0.42	-0.96	-0.89	0.89	-0.52	-0.85	-0.9	-0.68	-0.76	-0.68	-0.91	0.78	-0.74
Property Plant Equipment	-0.24	-0.24	-0.17	-0.37	-0.05	-0.3	-0.23	-0.3	-0.06	-0.4	0.12	-0.23	0.42		-0.34	-0.19	0.45	-0.54	-0.35	-0.41	-0.61	-0.25	-0.37	-0.3	0.36	-0.37
Good Will	0.98	0.97	0.92	0.98	0.57	0.92	0.98	0.9	0.87	0.76	0.42	0.96	-0.96	-0.34		0.91	-0.89	0.4	0.92	0.86	0.54	0.75	0.79	0.95	-0.68	0.81
Intangible Assets	0.89	0.88	0.91	0.88	0.72	0.84	0.89	0.78	0.77	0.56	0.57	0.91	-0.89	-0.19	0.91		-0.82	0.34	0.81	0.9	0.43	0.79	0.58	0.94	-0.63	0.68
Net Tangible Assets	-0.81	-0.75	-0.87	-0.92	-0.33	-0.68	-0.84	-0.66	-0.72	-0.66	-0.08	-0.88	0.89	0.45	-0.89	-0.82		-0.57	-0.93	-0.73	-0.78	-0.71	-0.69	-0.93	0.66	-0.73
Total Permanent Equity	0.29	0.27	0.34	0.49	0.07	0.34	0.31	0.29	0.32	0.27	-0.25	0.33	-0.52	-0.54	0.4	0.34	-0.57		0.44	0.37	0.81	0.33	0.32	0.41	-0.5	0.33
Long Term Debt Total	0.88	0.84	0.9	0.94	0.26	0.76	0.89	0.76	0.84	0.81	0.14	0.95	-0.85	-0.35	0.92	0.81	-0.93	0.44		0.71	0.59	0.79	0.85	0.94	-0.47	0.85
Capital Surpluse	0.85	0.85	0.76	0.81	0.69	0.86	0.84	0.82	0.65	0.59	0.67	0.79	-0.9	-0.41	0.86	0.9	-0.73	0.37	0.71		0.46	0.75	0.62	0.85	-0.71	0.73
Deferred Long Term Liab	0.4	0.35	0.5	0.63	0.06	0.34	0.44	0.3	0.36	0.37	-0.26	0.47	-0.68	-0.61	0.54	0.43	-0.78	0.81	0.59	0.46		0.44	0.37	0.55	-0.66	0.45
Long Term Investments	0.72	0.71	0.76	0.78	0.31	0.66	0.69	0.63	0.61	0.75	0.34	0.79	-0.76	-0.25	0.75	0.79	-0.71	0.33	0.79	0.75	0.44		0.66	0.82	-0.25	0.71
Short Long Term Debt	0.8	0.79	0.62	0.81	0.08	0.76	0.79	0.82	0.8	0.9	0.17	0.74	-0.68	-0.37	0.79	0.58	-0.69	0.32	0.85	0.62	0.37	0.66		0.74	-0.32	0.95
Net Invested Capital	0.91	0.88	0.94	0.95	0.51	0.8	0.92	0.78	0.83	0.74	0.36	0.96	-0.91	-0.3	0.95	0.94	-0.93	0.41	0.94	0.85	0.55	0.82	0.74		-0.58	0.79
Net Working Capital	-0.64	-0.62	-0.56	-0.66	-0.6	-0.64	-0.67	-0.58	-0.49	-0.22	-0.36	-0.54	0.78	0.36	-0.68	-0.63	0.66	-0.5	-0.47	-0.71	-0.66	-0.25	-0.32	-0.58		-0.45
Capital Stock	0.81	0.79	0.65	0.84	0.17	0.76	0.81	0.81	0.81	0.85	0.28	0.74	-0.74	-0.37	0.81	0.68	-0.73	0.33	0.85	0.73	0.45	0.71	0.95	0.79	-0.45

Click cells to compare fundamentals

Amedisys Total Debt Historical Pattern

Today, most investors in Amedisys Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Amedisys' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Amedisys total debt as a starting point in their analysis.

Amedisys Total Debt

Timeline

In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Competition

Predict Amedisys

Short Long Term Debt Total Over Time

Amedisys Short Long Term Debt Total

Short Long Term Debt Total

511.57 Million

At present, Amedisys' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.

Based on the latest financial disclosure, Amedisys has a Total Debt of 487.21 M. This is 82.29% lower than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The total debt for all United States stocks is 90.84% higher than that of the company.

Amedisys Total Debt Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amedisys' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amedisys could also be used in its relative valuation, which is a method of valuing Amedisys by comparing valuation metrics of similar companies.

Amedisys is currently under evaluation in total debt category among related companies.

Amedisys Institutional Holders

Institutional Holdings refers to the ownership stake in Amedisys that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Amedisys' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Amedisys' value.

		Shares
Melqart Asset Management (uk) Ltd.	2023-12-31	653.8 K
Magnetar Financial Llc	2023-12-31	618.9 K
Alliancebernstein L.p.	2023-12-31	545.1 K
Geode Capital Management, Llc	2023-12-31	527.5 K
Dimensional Fund Advisors, Inc.	2023-12-31	511.6 K
Cresset Asset Management, Llc	2023-12-31	454.4 K
Van Lanschot Kempen Investment Management Nv	2023-12-31	451.2 K
Woodline Partners Lp	2023-12-31	446.7 K
Marshall Wace Asset Management Ltd	2023-12-31	406.6 K
Vanguard Group Inc	2023-12-31	3.2 M
Blackrock Inc	2023-12-31	3 M

Amedisys Fundamentals

	Return On Equity	-0.0098
	Return On Asset	0.0598
	Profit Margin	(0) %
	Operating Margin	0.08 %
	Current Valuation	3.37 B
	Shares Outstanding	32.67 M
	Shares Owned By Insiders	2.26 %
	Shares Owned By Institutions	95.12 %
	Number Of Shares Shorted	2.49 M
	Price To Earning	15.03 X
	Price To Book	2.81 X
	Price To Sales	1.34 X
	Revenue	2.24 B
	Gross Profit	453.98 M
	EBITDA	216.91 M
	Net Income	(9.75 M)
	Cash And Equivalents	17.96 M
	Cash Per Share	0.55 X
	Total Debt	487.21 M
	Debt To Equity	0.53 %
	Current Ratio	1.06 X
	Book Value Per Share	32.65 X
	Cash Flow From Operations	137.19 M
	Short Ratio	7.11 X
	Earnings Per Share	(0.30) X
	Price To Earnings To Growth	1.35 X
	Target Price	97.78
	Number Of Employees	19 K
	Beta	0.86
	Market Capitalization	2.95 B
	Total Asset	2.06 B
	Retained Earnings	747.92 M
	Working Capital	23.21 M
	Current Asset	175.26 M
	Current Liabilities	175.19 M
	Net Asset	2.06 B

About Amedisys Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Amedisys's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amedisys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amedisys based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Amedisys

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amedisys position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amedisys will appreciate offsetting losses from the drop in the long position's value.

Moving together with Amedisys Stock

0.75	DH	Definitive Healthcare Financial Report 2nd of May 2024	Pair Corr
0.84	GH	Guardant Health Upward Rally	Pair Corr
0.75	FIGS	Figs Inc Financial Report 2nd of May 2024	Pair Corr

Moving against Amedisys Stock

0.83	GCTK	GlucoTrack	Pair Corr
0.75	WGS	GeneDx Holdings Corp Earnings Call This Week	Pair Corr
0.55	RCM	R1 RCM Inc Financial Report 2nd of May 2024	Pair Corr
0.49	HQY	HealthEquity Financial Report 3rd of June 2024	Pair Corr

The ability to find closely correlated positions to Amedisys could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amedisys when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amedisys - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amedisys to buy it.

The correlation of Amedisys is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amedisys moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amedisys moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Amedisys can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:

How To Invest In Amedisys

Details

Is Amedisys Stock a good investment?

Details

What is Amedisys' Net Worth?

Details

Largest Health Care Providers & Services Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Amedisys Piotroski F Score and Amedisys Altman Z Score analysis.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

Note that the Amedisys information on this page should be used as a complementary analysis to other Amedisys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Amedisys Stock analysis

When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.

	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets

Is Amedisys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.40)

Earnings Share

(0.30)

Revenue Per Share

68.603

Quarterly Revenue Growth

0.016

Return On Assets

0.0598

The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amedisys Stock Total Debt

Amedisys Company Total Debt Analysis

Total Debt

Bonds

+

Notes

Current Amedisys Total Debt

Amedisys Total Debt Driver Correlations

Amedisys Total Debt Historical Pattern

Amedisys Short Long Term Debt Total

Short Long Term Debt Total

511.57 Million

Amedisys Total Debt Peer Comparison

Amedisys Institutional Holders

Amedisys Fundamentals

About Amedisys Fundamental Analysis

Pair Trading with Amedisys

Moving together with Amedisys Stock

Moving against Amedisys Stock

Complementary Tools for Amedisys Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY